Igene Biotechnology Stock Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Igene Biotechnology are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Igene Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Igene Biotechnology is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Igene |
Igene Biotechnology Relative Risk vs. Return Landscape
If you would invest 0.00 in Igene Biotechnology on November 1, 2025 and sell it today you would earn a total of 0.00 from holding Igene Biotechnology or generate 0.0% return on investment over 90 days. Igene Biotechnology is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Igene, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Igene Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Igene Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Igene Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Igene Biotechnology generated a negative expected return over the last 90 days | |
| Igene Biotechnology has some characteristics of a very speculative penny stock | |
| Igene Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.96 M. Net Loss for the year was (140.75 K) with profit before overhead, payroll, taxes, and interest of 1.02 M. | |
| Igene Biotechnology currently holds about 269.29 K in cash with (97.05 K) of positive cash flow from operations. |
Igene Biotechnology Fundamentals Growth
Igene Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Igene Biotechnology, and Igene Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Igene Pink Sheet performance.
| Return On Asset | -0.0821 | |||
| Operating Margin | (124.22) % | |||
| Current Valuation | 1.1 M | |||
| Shares Outstanding | 1.57 B | |||
| Price To Earning | (0.10) X | |||
| Price To Sales | 2.28 X | |||
| Revenue | 3.96 M | |||
| EBITDA | (426.98 K) | |||
| Cash And Equivalents | 269.29 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (97.05 K) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 4.76 M | |||
| Retained Earnings | (54.86 M) | |||
| Current Asset | 2.44 M | |||
| Current Liabilities | 2.13 M | |||
About Igene Biotechnology Performance
By analyzing Igene Biotechnology's fundamental ratios, stakeholders can gain valuable insights into Igene Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Igene Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Igene Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.Things to note about Igene Biotechnology performance evaluation
Checking the ongoing alerts about Igene Biotechnology for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Igene Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Igene Biotechnology generated a negative expected return over the last 90 days | |
| Igene Biotechnology has some characteristics of a very speculative penny stock | |
| Igene Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.96 M. Net Loss for the year was (140.75 K) with profit before overhead, payroll, taxes, and interest of 1.02 M. | |
| Igene Biotechnology currently holds about 269.29 K in cash with (97.05 K) of positive cash flow from operations. |
- Analyzing Igene Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Igene Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Igene Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Igene Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Igene Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Igene Biotechnology's pink sheet. These opinions can provide insight into Igene Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Igene Pink Sheet analysis
When running Igene Biotechnology's price analysis, check to measure Igene Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Igene Biotechnology is operating at the current time. Most of Igene Biotechnology's value examination focuses on studying past and present price action to predict the probability of Igene Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Igene Biotechnology's price. Additionally, you may evaluate how the addition of Igene Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |